Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Dario GiuglianoMaria Ida MaiorinoMiriam LongoGiuseppe BellastellaPaolo ChiodiniKatherine EspositoPublished in: Endocrine (2019)
In T2D, SGLT-2i can reduce the risk of HF that is unrelated to improved glycemic control; DPP-4i and GLP-1 RAs behave as neutral.